Abivax to present three abstracts for obefazimod in ulcerative colitis at the ueg week 2024

Abivax to present three abstracts for obefazimod in ulcerative colitis at the ueg week 2024 professor bruce e. sands, md to present oral presentation of phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (uc) two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with uc paris, france, september 26, 2024 – 08:30 a.m.
ABVX Ratings Summary
ABVX Quant Ranking